Leqembi to Cost 2.98 Million Yen per Year, Re-Pricing Might Be Triggered on Patient Upswing

Chuikyo General Assembly Meeting on Dec. 13 A key Japanese health ministry panel on December 13 gave the go-ahead for Eisai’s Alzheimer’s therapy Leqembi (lecanemab) to be available at an annual cost of around 2.98 million yen per patient in...read more